Nasal spray mumps vaccine trial launches in healthy adults
NCT ID NCT06967181
First seen Jan 06, 2026 · Last updated May 23, 2026 · Updated 18 times
Summary
This early-stage trial tests two new nasal spray vaccines (CVM150 and CVM26) designed to protect against mumps. About 60 healthy adults aged 18-29 will receive the vaccine and be monitored for side effects and immune response over 12 months. The goal is to see if these vaccines are safe and trigger the body's defenses against the mumps virus.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MUMPS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Cincinnati Children's Hospital Medical Center Vaccine Research Center
Cincinnati, Ohio, 45229, United States
-
Coastal Carolina Research Center
North Charleston, South Carolina, 29405, United States
-
University Of Rochester Medical Center
Rochester, New York, 14642, United States
Conditions
Explore the condition pages connected to this study.